AC Immune/Roche Drop Crenezumab After Phase III CREAD Alzheimer's Failure

Interim top-line data from CREAD 1 and 2 indicate crenezeumab is unlikely to meet its primary endpoints and the studies are being stopped, but a clinical study in Colombia in familial Alzheimer’s is set to continue.